Tulip Sponsors FDA Study for COVID-19 Patients
Just published in the Journal of Current Medical Research and Opinion
SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.
Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.
Tulip Medical is grateful to have the opportunity to sponsor this trial and provide surgical instrumentation for it.
Share thoughts, questions, and comments on this article.
SDARTs faculty member, Ramon Llull, MD, PhD, presented at the IMCAS Annual Word Congress 2020 about the science of adipose therapies. Further, Dr. Daniele Bollero (plastic surgeon, Italy) presented on